Last reviewed · How we verify
normal salin
Normal saline, marketed by Shiraz University of Medical Sciences, is a widely used solution in medical settings. The key composition patent is set to expire in 2028, providing a period of exclusive market protection. The primary risk is the potential increase in competition post-patent expiry.
At a glance
| Generic name | normal salin |
|---|---|
| Also known as | no other name |
| Sponsor | Shiraz University of Medical Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Sedation on Rebound Pain in Knee Arthroplasty (NA)
- The Postoperative Lidocaine and Ketamine Effects on Morphine Requirement in Bariatric Surgery
- Dexmedetomine as Adjuvant for Spinal Anesthesia in Elective Cesarian Sections : a Pilot Study (PHASE3)
- The Effect of Perineural Dextrose Injection in Patients With Ulnar Neuropathy at the Elbow (NA)
- Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants (NA)
- The Combination Effect of Platelet-rich Plasma and Hyaluronic Acid for Knee Osteoarthritis (NA)
- The Effect of Manual Lymphatic Drainage (NA)
- Evaluation of the Efficacy of Prolotherapy Treatment in Patients With Plantar Fasciitis: a Randomized Double-blind Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- normal salin CI brief — competitive landscape report
- normal salin updates RSS · CI watch RSS
- Shiraz University of Medical Sciences portfolio CI